Bernstein raised the firm’s price target on HCA Healthcare (HCA) to $417 from $404 and keeps a Market Perform rating on the shares. The company’s Q2 outperformed on margins despite a deceleration in volumes, the analyst tells investors in a research note. The firm sees risks to HCA’s margins going forward from comp ratio and policy impacts to bad debt.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- Balanced Outlook on HCA Healthcare: Strong Margins Amid Slower Growth and Policy Risks
- HCA Healthcare price target raised to $423 from $380 at Baird
- HCA Healthcare’s Earnings Call: Strong Growth Amid Challenges
- HCA Healthcare price target lowered to $400 from $410 at Morgan Stanley
- HCA Healthcare price target raised to $380 from $361 at TD Cowen